EDMONTON, May 14, 2014 /CNW/ - On May 21, SinoVeda Canada Inc. will announce the results of a 6-month double-blind, randomized comparative clinical trial in post-menopausal women. The study compared EffectiCal®, a new scientifically formulated calcium supplement, against a leading global calcium brand and evaluated measures of bone health and gastrointestinal side effects. EffectiCal® represents a significant new innovation with the potential to play a global role in the maintenance of bone health and reducing the risk of developing osteoporosis.
Osteoporosis is a medical condition characterized by low bone density and deterioration of bone tissue. As the bones weaken over time, patients are at increased risk of bone fracture, its associated morbidities and mortality. Individuals at risk for osteoporosis include those that are sedentary, have low calcium intake, and the elderly, particularly post-menopausal women. Globally, it is estimated that over 200 million people suffer from osteoporosis1, including over 1.4 million in Canada2. With increasing prevalence due to an aging population, the cost of treating osteoporotic hip fractures alone is projected to exceed over $130 billion by the year 20503.
|What:||Clinical trial results comparing EffectiCal® against a leading global calcium brand|
|Who:||Dr. Richard Fedorak, Principal Investigator, Professor of Medicine, University of Alberta|
|Dr. Yun Tam, President, Chief Scientific Officer, and Co-founder, SinoVeda Canada Inc.|
|When:||Wednesday, May 21 | 10:30 AM|
|Formal presentation to start at 11 AM|
|Where:||Advanced Technology Centre, Edmonton Research Park|
|9650 20 avenue, Edmonton, AB T6N 1G1|
SinoVeda Canada Inc. is a privately held Edmonton-based health science company that uses botanical sources to develop and commercialize nutritional food ingredients, pharmaceutical-grade natural health products, and prescription medicines.
SinoVeda's patented Pharmaceutical Platform Technology® (PPT) allows the company to isolate, quantify, and standardize the active, absorbable ingredients from botanical sources, enabling the production of unique multiple-active, multiple-target, and patentable products.
|1||Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992 Nov;2(6):285-9|
|2||Goeree R, O'Brien B, Pettitt D, et al. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynaecol Can 1996 18:15.|
|3||Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med. 1997 Aug 18;103(2A):20S-25S; discussion 25S-26S.|
SOURCE: SinoVeda Canada Inc.
For further information:
To register or for more information, please contact Gordon Ngan, VP Business Development
P: 416 818-7217, E:email@example.com